💊 B12 Deficiency Reversibility Window Simulator

Early Neurologic Symptom Onset

Placeholder: paresthesia and gait changes mark the first detectable nerve stress.

• Paresthesia: First symptom (Placeholder short note.)
• Gradual: Typical onset (Placeholder short note.)
• Peripheral: Nerve fibers affected (Placeholder short note.)
• Serum B12: Detection method (Placeholder short note.)

Subacute combined degeneration begins

Placeholder: dorsal column fibers are affected first.

Symptom recognition delay

Placeholder: vague symptoms often delay diagnosis.

Demyelination Progression

Placeholder: myelin sheath breakdown accelerates with time and severity.

• Methylmalonyl-CoA: Mechanism (Placeholder short note.)
• Time-dependent: Progression (Placeholder short note.)
• Slows / blocks: Conduction (Placeholder short note.)
• Yes: Reversible early (Placeholder short note.)

Myelin thinning mechanism

Placeholder: abnormal fatty acids disrupt myelin structure.

Conduction velocity decline

Placeholder: nerve signals slow as sheath degrades.

Treatment Initiation Timing

Placeholder: when B12 replacement starts strongly shapes the outcome.

• IM B12: Standard therapy (Placeholder short note.)
• Days–weeks: Response speed (Placeholder short note.)
• Full recovery likely: Early treatment (Placeholder short note.)
• Partial recovery: Late treatment (Placeholder short note.)

Replacement protocol

Placeholder: repeated injections restore serum B12 levels.

Timing determines outcome

Placeholder: earlier treatment start improves nerve recovery odds.

Reversibility Window Threshold

Placeholder: a critical duration separates reversible from fixed damage.

• ~3–9 months: Typical window (Placeholder short note.)
• Shortens window: Severity effect (Placeholder short note.)
• Intact vs degenerated: Axon status (Placeholder short note.)
• Early screening: Clinical priority (Placeholder short note.)

Threshold variability

Placeholder: window length varies with severity and individual factors.

Axonal versus myelin injury

Placeholder: axon loss, not just myelin loss, blocks recovery.

Permanent Damage Risk Beyond the Window

Placeholder: delayed treatment leaves scarred, non-recovering nerve segments.

• Gliosis: Scar tissue (Placeholder short note.)
• Capped: Recovery ceiling (Placeholder short note.)
• Common: Residual deficit (Placeholder short note.)
• Early screening: Prevention (Placeholder short note.)

Irreversible axonal loss

Placeholder: degenerated axons do not regenerate their original path.

Residual disability

Placeholder: patients may retain permanent gait or sensory deficits.